Stereotaxis price to book ratio STXS

Market value divided by the book value of the company's net assets, since 2018.

Today, Oct 23, 2026: 8.3×
8-year median: 12.6×
Against its 8-year history: 27th; percentile: 0 is its lowest day, 100 its highest
8-year range: 4.1× to 196×
Peer median: 1.9×

Stereotaxis' price to book ratio is 8.3× as of Oct 23, 2026.

That is below its 8-year median of 12.6×, lower than on 73% of days in the last 8 years.

Over that time it ranged from 4.1× in Oct 2022 to 196× in Oct 2025.

The median for 10 healthcare stocks of a similar size is 1.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	8.3×	8.3×	39.9×
2025	36.6×	14.3×	196×
2024	17.9×	7.5×	18.7×
2023	7.6×	4.7×	8.5×
2022	5.6×	4.1×	13.3×
2021	13.4×	9.8×	20.7×
2020	10.7×	6.5×	17.5×
2019	14.7×	11.1×	104×
2018	38.3×	18.8×	52.6×

Against its peers

Companies in Healthcare nearest Stereotaxis' size, closest first, today.

Company	Price to book ratio
STXSStereotaxis	8.3×
KEQUKewaunee Scientific	1.3×
ICCCImmucell	3.0×
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
APTAlpha Pro Tech	0.9×
PDEXPro DEX	4.2×
PLXProtalix BioTherapeutics	2.9×
NATRNatures Sunshine Products	1.3×
ATNMActinium Pharmaceuticals	1.6×
ELMDElectromed	4.1×
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Stereotaxis

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.